News

Nursing leaders face rising burnout and turnover as four generations work side by side in today’s evolving health care workforce.

Retifanlimab plus chemotherapy improved survival and response rates in advanced anal cancer with manageable safety in phase 3 findings.

Oncology professionals can support cancer survivors after treatment through prevention-focused follow-up, education and survivorship care.

Young adults are increasingly being diagnosed with colorectal cancer, prompting experts to raise awareness about symptoms and risks.

Mayo Clinic health tech expert Matthew Byrne discussed how AI may improve oncology nursing workflows while preserving human-centered patient care.

Study findings suggest biologic aging and neighborhood deprivation may shape cognitive benefits from exercise after breast cancer.

A study presented at ONS 2026 shows how primary palliative care interventions improve patient-provider relationships and goal-setting in cellular therapy.

The FDA approved T-DXd for neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, showing improved pCR and IDFS rates.

Cedars-Sinai used a nursing education framework to shift a 63-bed oncology unit to a progressive care model, improving immunotherapy monitoring.

FDA approves atezolizumab and a companion diagnostic for adjuvant treatment of MIBC in patients with detected circulating tumor DNA after surgery.

Hackensack researchers evaluated an antineoplastic agent onboarding program for nurses treating solid and hematologic tumors.

New data from the ONS Congress suggest that chemotherapy-induced peripheral neuropathy may persist for years in survivors of frontline lymphoma care.

Pilot study links gut microbiome patterns to fatigue and pain in melanoma patients receiving immune checkpoint inhibitors.

A UAMS study shows non-musical sound machines significantly reduce patient anxiety during gynecology oncology appointments in a cost-effective way.

Both pre- and post-evidence–based practice change occlusion rates were low with relation to anticipated rates among hospitalized adult patients with cancer.

Jill Winther earned the 2026 Extraordinary Healer® Award for her leadership, advocacy and dedication to oncology nursing.

The FDA approved oral decitabine/cedazuridine and venetoclax for AML. Research showed a 41.6% complete remission rate in chemo-ineligible adults

The FDA approved sonrotoclax for R/R mantle cell lymphoma. Nurses must manage a 4-week dose ramp-up to prevent TLS for patients after prior BTK therapy.

A new survey reveals 53% of rural cancer patients struggle with costs, highlighting urgent needs for patient navigation and policy reform.

Experts warn of "molecular anxiety" and financial toxicity as ctDNA testing enters early-stage breast cancer surveillance.

New research identifies a significant link between immune checkpoint inhibitors and peripheral artery disease, prompting a need for nurse monitoring.

MD Anderson’s trial uses psilocybin to help oncology patients overcome anxiety and depression during maintenance therapy.

Learn about the FDA approval of vepdegestrant (Veppanu), the first PROTAC for ESR1-mutated breast cancer, including nursing priorities and side effects.

FDA approved zenocutuzumab-zbco for post-systemic-therapy, NRG1 fusion–positive unresectable/metastatic cholangiocarcinoma, addressing an ultra-rare molecular subset with limited options.

A study conducted by SEER and Medicare revealed that nearly half of older patients diagnosed with metastatic non-small cell lung cancer never received systemic therapy.

Dr. Jennifer Bickel said system-level wellness supports care teams, improving patient safety, experience and outcomes in oncology care.

Gedatolisib Improves Progression-Free Survival in PIK3CA-Mutant HR+/HER2- Metastatic Breast Cancer Versus Alpelisib Combination Therapy

FDA approved Veppanu for ER+, HER2- ESR1-mutated breast cancer after endocrine therapy, improving PFS to 5 months vs 2.1 and reducing progression risk by 43%.